Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Says Last Pre-Shire Quarter ‘Robust’, But Quiet On Divestments

Executive Summary

Takeda saw continued growth for mainstay drugs in what it described as a ‘robust’ last quarter of reporting before the inclusion of Shire, with global blockbuster Entyvio leading the way, but gave away little new on widely anticipated post-deal divestments.

You may also be interested in...



Myeloma Milestones: Selinexor May Be Next Novel Agent While Established Drugs Expand Indications

Karyopharm's selinexor could be the next novel drug approved for multiple myeloma, which has seen a deluge of new treatment regimens. With room for improvement, the pipeline is full of milestones for approved and new therapies.

All Eyes On Early Post-Shire Performance Ahead Of Takeda Q4

The first real indications of how Shire is contributing to Takeda will come when the Japanese firm issues its annual results next week, and investors will also be keeping a keen eye on the critical first forward guidance for the combined company.

Takeda Executive Rejig In ICMEA Region As Shire Integration Shapes

Takeda has shuffled certain key executive positions in the ICMEA (India, CIS, the Middle East and Africa) region where it hopes to sharpen its focus, while also emerging more agile as the integration with Shire advances.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel